The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global POEMS Syndrome Market Research Report 2025
Synopsis
POEMS syndrome is a rare blood disorder that damages your nerves and affects other parts of your body. POEMS stands for these signs and symptoms: Polyneuropathy. Numbness, tingling and weakness in your legs — and over time, maybe in your hands — and difficulty breathing.
Global POEMS Syndrome market is projected to reach US$ 1428.3 million in 2029, increasing from US$ 980 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole POEMS Syndrome market research.
The global POEMS syndrome market refers to the market for diagnosing and treating POEMS syndrome, a rare multisystem disorder. POEMS syndrome is a rare plasma cell disorder that affects multiple systems, including the peripheral nerves, bone marrow, and blood vessels. The acronym “POEMS” stands for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes.
The market for POEMS syndrome is driven by several factors, including the increasing prevalence of the condition, advancements in diagnostic techniques, and the development of targeted treatment options. POEMS syndrome is usually diagnosed through a combination of clinical symptoms, specialized laboratory tests, imaging studies, and biopsy of affected tissues. Accurate and early diagnosis is crucial to initiate appropriate treatment and manage complications.
Treatment options for POEMS syndrome depend on individual patient characteristics, disease severity, and involvement of different systems. The main treatment approach is to target the underlying plasma cell disorder. High-dose chemotherapy with autologous stem cell transplantation (ASCT) is commonly used to achieve disease control and improve outcomes. Immunomodulatory drugs, corticosteroids, and radiation therapy may also be used alone or in combination.
Geographically, North America and Europe are major contributors to the global POEMS syndrome market due to well-established healthcare systems, advanced treatment facilities, and a higher prevalence of the condition. The market in the Asia-Pacific region is also expanding due to improving healthcare infrastructure, increased awareness, and rising cases of POEMS syndrome. There may be geographical variations in disease presentation, management, and access to treatment options.
Key players in the global POEMS syndrome market include pharmaceutical companies, research institutions, and healthcare providers specialized in hematologic malignancies. These players focus on developing novel treatment options, conducting clinical trials, and collaborating with patients and patient advocacy groups to improve patient outcomes and quality of life.
Challenges in the market include the rarity of the condition, delayed diagnosis due to variable and non-specific symptoms, and limited understanding of the disease mechanisms. Research efforts are ongoing to better understand the pathogenesis of POEMS syndrome and explore new therapeutic targets. Early detection, multidisciplinary management, and ongoing medical care are crucial for improving outcomes in POEMS syndrome patients.
In summary, the global POEMS syndrome market is driven by factors such as the increasing prevalence of the condition, advancements in diagnostic techniques, and the development of targeted treatment options. North America and Europe currently lead the market, but the Asia-Pacific region is also growing. Key players in the market continue to focus on research and development to improve patient outcomes and overall quality of life.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global POEMS Syndrome market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Bristol Myers Squibb
Baxter International
Genentech
Takeda Pharmaceuticals U.S.A.
Oncopeptides
Acrotech Biopharma LLC
LGM Pharma, LLC
Jubilant Cadista Pharmaceuticals Inc
Segment by Type
Chemotherapy
Radiation Therapy
Physical Therapy
Others
Segment by Application
Hospitals
Specialty Clinics
Outpatient Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The POEMS Syndrome report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
POEMS syndrome is a rare blood disorder that damages your nerves and affects other parts of your body. POEMS stands for these signs and symptoms: Polyneuropathy. Numbness, tingling and weakness in your legs — and over time, maybe in your hands — and difficulty breathing.
Global POEMS Syndrome market is projected to reach US$ 1428.3 million in 2029, increasing from US$ 980 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole POEMS Syndrome market research.
The global POEMS syndrome market refers to the market for diagnosing and treating POEMS syndrome, a rare multisystem disorder. POEMS syndrome is a rare plasma cell disorder that affects multiple systems, including the peripheral nerves, bone marrow, and blood vessels. The acronym “POEMS” stands for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes.
The market for POEMS syndrome is driven by several factors, including the increasing prevalence of the condition, advancements in diagnostic techniques, and the development of targeted treatment options. POEMS syndrome is usually diagnosed through a combination of clinical symptoms, specialized laboratory tests, imaging studies, and biopsy of affected tissues. Accurate and early diagnosis is crucial to initiate appropriate treatment and manage complications.
Treatment options for POEMS syndrome depend on individual patient characteristics, disease severity, and involvement of different systems. The main treatment approach is to target the underlying plasma cell disorder. High-dose chemotherapy with autologous stem cell transplantation (ASCT) is commonly used to achieve disease control and improve outcomes. Immunomodulatory drugs, corticosteroids, and radiation therapy may also be used alone or in combination.
Geographically, North America and Europe are major contributors to the global POEMS syndrome market due to well-established healthcare systems, advanced treatment facilities, and a higher prevalence of the condition. The market in the Asia-Pacific region is also expanding due to improving healthcare infrastructure, increased awareness, and rising cases of POEMS syndrome. There may be geographical variations in disease presentation, management, and access to treatment options.
Key players in the global POEMS syndrome market include pharmaceutical companies, research institutions, and healthcare providers specialized in hematologic malignancies. These players focus on developing novel treatment options, conducting clinical trials, and collaborating with patients and patient advocacy groups to improve patient outcomes and quality of life.
Challenges in the market include the rarity of the condition, delayed diagnosis due to variable and non-specific symptoms, and limited understanding of the disease mechanisms. Research efforts are ongoing to better understand the pathogenesis of POEMS syndrome and explore new therapeutic targets. Early detection, multidisciplinary management, and ongoing medical care are crucial for improving outcomes in POEMS syndrome patients.
In summary, the global POEMS syndrome market is driven by factors such as the increasing prevalence of the condition, advancements in diagnostic techniques, and the development of targeted treatment options. North America and Europe currently lead the market, but the Asia-Pacific region is also growing. Key players in the market continue to focus on research and development to improve patient outcomes and overall quality of life.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global POEMS Syndrome market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Bristol Myers Squibb
Baxter International
Genentech
Takeda Pharmaceuticals U.S.A.
Oncopeptides
Acrotech Biopharma LLC
LGM Pharma, LLC
Jubilant Cadista Pharmaceuticals Inc
Segment by Type
Chemotherapy
Radiation Therapy
Physical Therapy
Others
Segment by Application
Hospitals
Specialty Clinics
Outpatient Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The POEMS Syndrome report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global POEMS Syndrome Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Radiation Therapy
1.2.4 Physical Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global POEMS Syndrome Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Outpatient Surgery Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global POEMS Syndrome Market Perspective (2018-2029)
2.2 POEMS Syndrome Growth Trends by Region
2.2.1 Global POEMS Syndrome Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 POEMS Syndrome Historic Market Size by Region (2018-2023)
2.2.3 POEMS Syndrome Forecasted Market Size by Region (2024-2029)
2.3 POEMS Syndrome Market Dynamics
2.3.1 POEMS Syndrome Industry Trends
2.3.2 POEMS Syndrome Market Drivers
2.3.3 POEMS Syndrome Market Challenges
2.3.4 POEMS Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top POEMS Syndrome Players by Revenue
3.1.1 Global Top POEMS Syndrome Players by Revenue (2018-2023)
3.1.2 Global POEMS Syndrome Revenue Market Share by Players (2018-2023)
3.2 Global POEMS Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by POEMS Syndrome Revenue
3.4 Global POEMS Syndrome Market Concentration Ratio
3.4.1 Global POEMS Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by POEMS Syndrome Revenue in 2022
3.5 POEMS Syndrome Key Players Head office and Area Served
3.6 Key Players POEMS Syndrome Product Solution and Service
3.7 Date of Enter into POEMS Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 POEMS Syndrome Breakdown Data by Type
4.1 Global POEMS Syndrome Historic Market Size by Type (2018-2023)
4.2 Global POEMS Syndrome Forecasted Market Size by Type (2024-2029)
5 POEMS Syndrome Breakdown Data by Application
5.1 Global POEMS Syndrome Historic Market Size by Application (2018-2023)
5.2 Global POEMS Syndrome Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America POEMS Syndrome Market Size (2018-2029)
6.2 North America POEMS Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America POEMS Syndrome Market Size by Country (2018-2023)
6.4 North America POEMS Syndrome Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe POEMS Syndrome Market Size (2018-2029)
7.2 Europe POEMS Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe POEMS Syndrome Market Size by Country (2018-2023)
7.4 Europe POEMS Syndrome Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific POEMS Syndrome Market Size (2018-2029)
8.2 Asia-Pacific POEMS Syndrome Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific POEMS Syndrome Market Size by Region (2018-2023)
8.4 Asia-Pacific POEMS Syndrome Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America POEMS Syndrome Market Size (2018-2029)
9.2 Latin America POEMS Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America POEMS Syndrome Market Size by Country (2018-2023)
9.4 Latin America POEMS Syndrome Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa POEMS Syndrome Market Size (2018-2029)
10.2 Middle East & Africa POEMS Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa POEMS Syndrome Market Size by Country (2018-2023)
10.4 Middle East & Africa POEMS Syndrome Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer POEMS Syndrome Introduction
11.1.4 Pfizer Revenue in POEMS Syndrome Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb POEMS Syndrome Introduction
11.2.4 Bristol Myers Squibb Revenue in POEMS Syndrome Business (2018-2023)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Baxter International
11.3.1 Baxter International Company Detail
11.3.2 Baxter International Business Overview
11.3.3 Baxter International POEMS Syndrome Introduction
11.3.4 Baxter International Revenue in POEMS Syndrome Business (2018-2023)
11.3.5 Baxter International Recent Development
11.4 Genentech
11.4.1 Genentech Company Detail
11.4.2 Genentech Business Overview
11.4.3 Genentech POEMS Syndrome Introduction
11.4.4 Genentech Revenue in POEMS Syndrome Business (2018-2023)
11.4.5 Genentech Recent Development
11.5 Takeda Pharmaceuticals U.S.A.
11.5.1 Takeda Pharmaceuticals U.S.A. Company Detail
11.5.2 Takeda Pharmaceuticals U.S.A. Business Overview
11.5.3 Takeda Pharmaceuticals U.S.A. POEMS Syndrome Introduction
11.5.4 Takeda Pharmaceuticals U.S.A. Revenue in POEMS Syndrome Business (2018-2023)
11.5.5 Takeda Pharmaceuticals U.S.A. Recent Development
11.6 Oncopeptides
11.6.1 Oncopeptides Company Detail
11.6.2 Oncopeptides Business Overview
11.6.3 Oncopeptides POEMS Syndrome Introduction
11.6.4 Oncopeptides Revenue in POEMS Syndrome Business (2018-2023)
11.6.5 Oncopeptides Recent Development
11.7 Acrotech Biopharma LLC
11.7.1 Acrotech Biopharma LLC Company Detail
11.7.2 Acrotech Biopharma LLC Business Overview
11.7.3 Acrotech Biopharma LLC POEMS Syndrome Introduction
11.7.4 Acrotech Biopharma LLC Revenue in POEMS Syndrome Business (2018-2023)
11.7.5 Acrotech Biopharma LLC Recent Development
11.8 LGM Pharma, LLC
11.8.1 LGM Pharma, LLC Company Detail
11.8.2 LGM Pharma, LLC Business Overview
11.8.3 LGM Pharma, LLC POEMS Syndrome Introduction
11.8.4 LGM Pharma, LLC Revenue in POEMS Syndrome Business (2018-2023)
11.8.5 LGM Pharma, LLC Recent Development
11.9 Jubilant Cadista Pharmaceuticals Inc
11.9.1 Jubilant Cadista Pharmaceuticals Inc Company Detail
11.9.2 Jubilant Cadista Pharmaceuticals Inc Business Overview
11.9.3 Jubilant Cadista Pharmaceuticals Inc POEMS Syndrome Introduction
11.9.4 Jubilant Cadista Pharmaceuticals Inc Revenue in POEMS Syndrome Business (2018-2023)
11.9.5 Jubilant Cadista Pharmaceuticals Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
